Standard-of-Care Treatment for Patients with LR-MDS
A medical oncologist discusses standard-of-care treatment practices for patients with lower-risk myelodysplastic syndromes.
Video content above is prompted by the following:
- Briefly discuss a high-level overview of the standard of care (SOC) for patients with LR-MDS.
- How does your treatment decision-making change based on mutational burden (del(5q); SF3B1) and the presence, or not, of ring sideroblasts (RS)?
Recent Videos
Related Content
Exploring Factors Supporting TKI Discontinuation in Patients With Ph+ ALL
June 27th 2025Article
Recent studies reveal promising outcomes for discontinuing TKI therapy in select patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, suggesting potential long-term remission.
Read More
